A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O’RourkeDepartment of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USAMacLean P. NasrallahDivision of Neuropathology, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USAArati DesaiDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USAJ. Joseph MelenhorstCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USAKeith G. MansfieldNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USAJennifer J.D. MorrissetteDivision of Precision and Computational Diagnostics, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USAMaria Martinez‐LageDivision of Neuropathology, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USASteven BremDepartment of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USAEileen MaloneyDepartment of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USAAngela ShenNovartis Oncology, East Hanover, NJ 07936, USARandi IsaacsNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USASuyash MohanDivision of Neuroradiology, Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USAGabriela PlesaCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USASimon F. LaceyCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USAJean‐Marc NavenotCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USAZhaohui ZhengCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USABruce L. LevineCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USAHideho OkadaDepartment of Neurosurgery, University of California, San Francisco, San Francisco, CA 94143, USACarl H. JuneCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USAJennifer L. BrogdonNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USAMarcela V. MausCellular Immunotherapy Program, Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA 02129, USA
2017en
ABI
Abstract
A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms of resistance.
Identifiers
Citations and references
Cited by 30 references